Intangible Assets

AEMD does not appear to possess meaningful brand, patent, or regulatory-intangible advantages that would let it charge peers a premium or protect margins over 5–10 years.

The absence of disclosed durable margin history and the negative TTM ROIC/ROCE suggest any proprietary assets are not translating into sustained economic value versus peers.

Compared with established medtech peers that typically defend pricing through patents, clinical evidence, or regulatory scale, AEMD’s moat from intangibles looks materially weaker and more replicable.

Switching Costs

AEMD shows no evidence of embedded workflows, data lock-in, or contractual dependence that would make customers costly to displace versus peers.

Negative TTM ROIC and extremely weak operating efficiency are inconsistent with a business that retains customers through high switching friction.

Relative to peers with recurring consumables, installed-base service, or software-like integration, AEMD appears to have minimal switching-cost protection.

Network Effects

AEMD does not show a platform, marketplace, or data network that compounds value as more users participate.

There is no evidence that customer adoption by one party materially increases utility for other parties, unlike peer models with ecosystem-driven demand.

Compared with peers that benefit from referral, data, or ecosystem flywheels, AEMD has no observable network-effect moat.

Cost Advantage

AEMD’s negative ROIC and ROCE indicate it is not converting capital into returns efficiently enough to imply a durable unit-cost advantage versus peers.

The reported cash conversion cycle is highly negative, but without supporting margin or scale evidence it does not demonstrate a structural cost edge.

Relative to peers with manufacturing scale, procurement leverage, or process efficiency, AEMD does not show a defensible cost advantage.

Efficient Scale

AEMD does not appear to operate in a niche where a small number of firms can profitably serve the market and deter entry through scale economics.

The lack of positive return metrics suggests the company is not capturing the kind of fixed-cost absorption that would support efficient-scale protection versus peers.

Compared with peers in concentrated markets or regulated niches, AEMD shows no clear evidence that market size or structure limits competition in its favor.

Overall Score

AEMD’s moat appears weak versus peers because none of the five structural drivers show durable pricing power, retention, or scale-based protection, and the negative TTM profitability metrics reinforce that any competitive advantages are not translating into sustained economic returns.